Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-005314-29
    Sponsor's Protocol Code Number:QTM/OMN-0115
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2016-01-13
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-005314-29
    A.3Full title of the trial
    Randomized, open-label, two parallel group clinical trial, conducted under blinding evaluator conditions to compare the efficacy and tolerability of preservative-free formulation of Latanoprost 50µg/ml eye drops vs. Xalatan in patients with open-angle glaucoma or hypertension ocular.
    Ensayo clínico aleatorizado, no enmascarado para el paciente aunque enmascarado para el evaluador, con dos grupos en paralelos, para comparar la eficacia y tolerabilidad del colirio formulado con latanoprost 50µg/ml sin conservantes frente al colirio Xalatan en pacientes con glaucoma de ángulo abierto o hipertensión ocular.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Randomized, open-label, two parallel group clinical trial, conducted under blinding evaluator conditions to compare the efficacy and tolerability of preservative-free formulation of Latanoprost 50µg/ml eye drops vs. Xalatan in patients with open-angle glaucoma or hypertension ocular.
    Ensayo clínico aleatorizado, no enmascarado para el paciente aunque enmascarado para el evaluador, con dos grupos en paralelos, para comparar la eficacia y tolerabilidad del colirio formulado con latanoprost 50µg/ml sin conservantes frente al colirio Xalatan en pacientes con glaucoma de ángulo abierto o hipertensión ocular.
    A.4.1Sponsor's protocol code numberQTM/OMN-0115
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorOMNIVISION GmbH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportOmnivision GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationOmnivision
    B.5.2Functional name of contact pointMiriam Hoffmann
    B.5.3 Address:
    B.5.3.1Street AddressLindberghstr 7
    B.5.3.2Town/ cityPuchheim
    B.5.3.3Post codeD-82178
    B.5.3.4CountryGermany
    B.5.4Telephone number34968416581-
    B.5.5Fax number----
    B.5.6E-mailM.Hoffmann@omnivision-pharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLatanoprost 50 ug/ml
    D.3.4Pharmaceutical form Eye drops
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOcular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLatanoprost
    D.3.9.3Other descriptive nameLATANOPROST
    D.3.9.4EV Substance CodeSUB08409MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name XALATAN
    D.2.1.1.2Name of the Marketing Authorisation holderPfizer
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Eye drops
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOcular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLatanoprost
    D.3.9.3Other descriptive nameLATANOPROST
    D.3.9.4EV Substance CodeSUB08409MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Open Angle Glaucoma or Ocular Hypertension
    Glaucoma de ángulo abierto o Hipertensión ocular
    E.1.1.1Medical condition in easily understood language
    Open Angle Glaucoma or Ocular Hypertension
    Glaucoma de ángulo abierto o Hipertensión ocular
    E.1.1.2Therapeutic area Diseases [C] - Eye Diseases [C11]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    It is the objective of the clinical trial to confirm the clinical non-inferiority of the preservative-free latanoprost eye drops compared with the marketed preservative-containing Xalatan? by the average decrease of diurnal IOP measured between the first and last visit
    Confirmar la no inferioridad clínica de latanoprost sin conservantes en comparación con Xalatan colirio comercializado con conservantes, mediante la disminución media de la Presión Intraocular (PIO) diurna entre la primera y la última visita del estudio
    E.2.2Secondary objectives of the trial
    - The average decreases of diurnal IOP measured between baseline and day 7
    - The average decrease of diurnal IOP between baseline and day14
    - The proportion of patients with measured IOP <21 mmHg at the end of the clinical trial
    ? La reducción media de la PIO diurna entre la visita basal y el día 7
    ? La reducción media de la PIO diurna entre la visita basal y el día 14
    ? El número de pacientes con medida de PIO ?21 mmHg al final del ensayo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients being
    - male or female, of any race and ?18 years of age
    - diagnosed of unilateral or bilateral primary open angle glaucoma or ocular hypertension
    - on treatment with an IOP-lowering prostaglandin analogue for at least 6 months
    - on treatment with an IOP ?21 mmHg measured as the mean of both eyes at two measurements at least one hour apart
    - best-corrected visual acuity ?20 of 100 corresponding to logMAR of 0.7 in both eyes
    - in case of women, postmenopausal (>12 months without menstrual bleeding), surgically sterilized, or on use of effective birth control measures
    - expected by the investigator that IOP would remain controlled with the new treatment without optic nerve damage or progression of visual field loss
    - able to understand the requirements of the clinical trial and to agree to return for the required follow-up visits;
    - willing to provide voluntary written informed consent and data protection declaration before any clinical trial related procedure is performed.
    - Hombres y mujeres de cualquier raza y edad ? 18 años
    - Diagnosticados de de glaucoma primario de ángulo abierto o hipertensión ocular unilateral o bilateral.
    - En tratamiento con un reductor de la PIO análogo de prostaglandina durante al menos 6 meses
    - Que estén en tratamiento y tengan una PIO ?21 mmHg, determinada como la media de ambos ojos ( si bilateral) en dos mediciones realizadas al menos con una hora de diferencia
    -Con mejor agudeza visual corregida ?20 de 100 que corresponde en logMAR a 0,7 en ambos ojos
    - En el caso de las mujeres: que sean posmenopáusicas (>12 meses sin menstruación) o estén esterilizadas quirúrgicamente o usen medidas anticonceptivas eficaces
    - En los que el investigador prevea que la PIO permanecerá controlada con el nuevo tratamiento sin dañar el nervio óptico y sin que avance la pérdida del campo visual
    - Capaces de entender los requisitos del ensayo y que estén dispuestos a acudir a las visitas programadas
    - Dispuestos a otorgar voluntariamente su consentimiento informado por escrito y firmar la declaración de protección de datos antes de realizar cualquier procedimiento relacionado con el ensayo.
    E.4Principal exclusion criteria
    - a history of chronic or recurrent inflammatory eye disease, ocular trauma or infections;
    - clinically significant or progressive retinal disease;
    - intraocular surgery within the past 6 months;
    - ocular laser surgery within the past 3 months;
    - a change in glaucoma therapy within 1 month before the screening visit;
    - history of bronchial asthma, or severe chronic obstructive pulmonary disease; reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
    - treatment with local or systemic corticosteroids;
    - inability to discontinue the use of glucocorticoid medications;
    - not receiving stable doses of any medication that could affect IOP for 30 days before the beginning of the clinical trial (e.g. clonidine);
    - a history of allergic hypersensitivity or poor tolerance to any component of the eye drop solution used in this clinical trial or a contraindication of ß-adrenergic receptor antagonists due to systemic disease;
    - sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure or cardiogenic shock;
    - pregnancy or breast-feeding or childbearing potential not protected by a highly effective contraceptive method of birth control;
    - current participation or not yet completed period of at least 30 days since ending other investigational device or drug trial(s);
    - unwillingness or inability to comply with the clinical trial procedures;
    - unwillingness to consent to storage, saving and transmission of pseudonymous medical data for clinical trial reasons;
    - who are legally incapacitated,
    - who are legally detained in an official institute.
    - tratamiento previo para el glaucoma primario de ángulo abierto o hipertensión intraocular que no sea un análogo de prostaglandina
    - antecedentes de enfermedad inflamatoria ocular crónica o recurrente, traumatismos o infecciones oculares
    - glaucoma de ángulo estrecho o ángulo cerrado
    - retinopatía clínicamente importante o progresiva
    - cirugía intraocular en los 6 últimos meses
    - cirugía ocular con láser en los 3 últimos meses
    - cambio en el tratamiento del glaucoma en el mes anterior a la visita de selección
    - mejor agudeza visual corregida inferior a 0,7 logaritmo del ángulo mínimo de resolución (logMAR), ángulo muy estrecho o parcialmente cerrado, relación copa/disco >0,8b
    - antecedentes de asma bronquial o enfermedad pulmonar obstructiva crónica grave; enfermedad reactiva de las vías respiratorias, incluido el asma bronquial
    - tratamiento con corticosteroides locales o sistémicos
    - incapacidad para suspender el uso de glucocorticoides
    - que no reciban dosis estables de algún medicamento que pudiera afectar a la PIO en los 30 días anteriores al inicio del ensayo clínico (p. ej., clonidina)
    - antecedentes de hipersensibilidad alérgica o mala tolerancia a cualquier componente de la solución en colirio usada en este ensayo clínico o contraindicación de los antagonistas de los receptores adrenérgicos ß por enfermedad sistémica
    - bradicardia sinusal, bloqueo auriculoventricular de segundo o tercer grado, insuficiencia cardiaca franca o choque cardiogénico
    - embarazo o lactancia o edad fértil sin protección mediante un método anticonceptivo eficaz
    - participación actual o que no haya terminado todavía el periodo de al menos 30 días desde la finalización de la participación en otro(s) ensayo(s) clínico(s) de un fármaco o dispositivo en investigación
    - poca disposición o incapacidad para completar los procedimientos del ensayo clínico
    - poca disposición a otorgar el consentimiento para la conservación, grabación y transmisión de los datos médicos bajo pseudónimo por razones del ensayo clínico;
    - incapacidad legal,
    - detenidos legalmente en una institución oficial
    -
    E.5 End points
    E.5.1Primary end point(s)
    - Diurnal IOP measured by ocular tonometry (Goldmann Applanation Tonometry) between baseline and the last visit
    - PIO diurna medida mediante tonometría ocular (Tonómetro de Aplanación de Goldmann) entre la visita basal y la última visita
    E.5.1.1Timepoint(s) of evaluation of this end point
    First and last visit (At Day 0 and Day 28)
    En la visita basal (día 0) y en la visita final (día 28)
    E.5.2Secondary end point(s)
    - Diurnal IOP measured by ocular tonometry (Goldmann Applanation Tonometry) between baseline and day 7
    - Diurnal IOP measured by ocular tonometry (Goldmann Applanation Tonometry) between baseline and day14
    - The proportion of patients with measured IOP <21 mmHg at the end of the clinical trial
    - PIO diurna medida mediante tonometría ocular (Tonómetro de Aplanación de Goldmann) entre la visita basal y el día 7
    - PIO diurna medida mediante tonometría ocular (Tonómetro de Aplanación de Goldmann) entre la visita basal y el día 14
    - El número de pacientes con PIO?21 mmHg al final del ensayo clínico (visita final)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Day 7 and day 14
    Visita día 7 y visita día 14
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Cegado para el evaluador
    blinding evaluator conditions
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the trial is the last visit of the last subject
    El final del ensayo coincide con la última visita del ultimo paciente incluido
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months12
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 126
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state126
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    NONE
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-03-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-12-21
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2016-10-27
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:57:21 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA